Streetbeat News

OLK

Olink Holding AB (publ)

https://www.olink.com

CEO

Jon Heimer

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients.

Open

26.00

Mkt cap

3.2B

Volume

1.9M

High

26.08

P/E Ratio

-96.59

52-wk high

26.09

Low

25.98

Div yield

N/A

52-wk low

14.10

Novogene Asia Pacific Middle East and Africa has adopted Olink® Explore HT technology to accelerate multi-omics research with next-generation proteomics. The technology is expected to enhance Novogene's research capabilities.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 6:27 am

Thermo Fisher Scientific Inc. (TMO) has commenced a tender offer to acquire all outstanding common shares and American Depositary Shares (ADSs) of Olink Holding AB (OLK) for $26.00 per share and per ADS, in cash. The offer will expire on November 30, 2023, unless extended or terminated earlier. Olink's board of directors has recommended that shareholders accept the offer. Summa Equity AB, Olink's largest shareholder, and additional shareholders and management, holding approximately 66% of Olink's shares, have agreed to tender into the offer.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:46 pm

The article lists five overbought health care stocks, indicating they may be overvalued: Structure Therapeutics Inc. (GPCR), Olink Holding AB (OLK), Intercept Pharmaceuticals, Inc. (ICPT), NextGen Healthcare, Inc. (NXGN), and HealthStream, Inc. (HSTM). Overbought status is determined by the Relative Strength Index (RSI), with values above 70 indicating overbought conditions. The companies have recent news such as acquisition deals, private placements, and earnings reports.

Portfolio Pulse from Lisa Levin

October 26, 2023 | 12:49 pm

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Olink Holding (NASDAQ:OLK) and raised the price target from $18 to $26.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:33 pm

Scotiabank analyst Sung Ji Nam has downgraded Olink Holding (NASDAQ:OLK) from Sector Outperform to Sector Perform.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:27 pm

Bank of America Corp reported better-than-expected earnings for its third quarter, with EPS of $0.90, compared to $0.81 in the year-ago period, beating the consensus of $0.81. Revenue increased 3% year-over-year to $25.32 billion, beating the consensus of $25.14 billion. SciSparc Ltd. shares shot up 122% after Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Shares of Assembly Biosciences, Inc. got a boost after the company and Gilead announced a 12-year partnership. Olink Holding AB shares were also up after Thermo Fisher Scientific announced it will acquire the company. Evelo Biosciences, Inc. shares dropped 56% after releasing top-line results from its Phase 2 clinical study. Shares of NetScout Systems, Inc. were down after the company reported weak preliminary results for the second quarter and lowered its FY24 guidance. Monte Rosa Therapeutics, Inc. was down after announcing interim data from the Phase 1 dose escalation part of its ongoing phase 1/2 study.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 6:31 pm

The article lists the stocks that gained and lost in Tuesday's mid-day session. Notable gainers include SciSparc Ltd., Assembly Biosciences, Inc., and Olink Holding AB, while notable losers include Evelo Biosciences, Inc., Monte Rosa Therapeutics, Inc., and Nuvve Holding Corp. The article also mentions that ServisFirst Bancshares shares are trading lower by 6% after the company reported third-quarter earnings.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 5:42 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Nkarta, Assembly Biosciences, Olink Holding, Anebulo Pharmaceuticals, Moleculin Biotech, and OpGen saw their shares rise, while Evelo Biosciences, Monte Rosa Therapeutics, Celcuity, Tiziana Life Sciences, Better Therapeutics, and Nuvectis Pharma experienced a decline in their stock prices.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 5:31 pm

The Dow Jones rose by 100 points, while NASDAQ fell slightly. Goldman Sachs reported better-than-expected Q3 earnings, despite a decrease from the previous year. Energy shares climbed by 1%, while IT shares fell by 0.9%. SciSparc, Assembly Biosciences, and Olink Holding saw significant stock increases, while Evelo Biosciences, NetScout Systems, and Monte Rosa Therapeutics experienced decreases. Oil and gold prices rose slightly.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 3:56 pm

Despite a general downward trend in U.S. stocks, several companies recorded gains. Olink Holding AB's shares rose 65.8% after Thermo Fisher Scientific announced plans to acquire the company. Wyndham Hotels & Resorts, Inc. gained 11.2% following a proposal from Choice Hotels to acquire the company for $90.00 per share. Engaged Capital has built a significant stake in V.F. Corporation, leading to a 13.4% rise in its shares. Sensient Technologies Corporation's stock jumped 6.7% after Baird upgraded the stock from Neutral to Outperform.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 3:40 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.